NeuroPace 2025 Earnings: AI Ambitions, PMA-S Hurdles, and a 2026 Revenue Forecast On Deck

NeuroPace, Inc. (NPCE) released its fourth-quarter and full-year 2025 results, reinforcing the company’s trajectory in a narrow-but-persistent market for seizure-management devices. The press release highlights a solid Q4 revenue of $26.6 million, a 24% year-over-year rise, and a 2025 haul of $100.0 million in total revenue—up about 25% from 2024. As with many device plays, the real question is how the company turns that top-line momentum into durable profitability, especially with ongoing regulatory bets and a push into AI-assisted tools. For fans of the usual earnings shorthand, NPCE also touches on EBITDA, margins, and an explicit 2026 revenue forecast embedded in its core RNS system growth plan. Note: the release does not provide EPS data in this quarter, so investors will be watching for an earnings-per-share figure and potential EPS consensus in upcoming reports.

Quarterly and Full-Year Financial Highlights

Ticker: NPCE — NeuroPace, Inc. reported Q4 2025 revenue of $26.6 million, up 24% from Q4 2024; full-year 2025 revenue totaled $100.0 million, up 25% year over year.
Product mix: RNS System revenue was $22.4 million in Q4, a 26% YoY increase; full-year RNS revenue was $81.7 million, representing a similar growth pace.
Margins: Total gross margin stood at 77.4% in Q4, with the RNS gross margin at 80.5% (a 40 bp improvement year over year). Full-year gross margin was 77.2% (RNS gross margin 81.9%), marking a meaningful margin expansion alongside positive product mix and manufacturing efficiency.
Profitability: Adjusted EBITDA for Q4 was $0.9 million—marking the second consecutive quarter near the breakeven line.
Liquidity: Cash, cash equivalents and short-term investments totaled $61.1 million as of December 31, 2025, up about $1.0 million from September 30, 2025.

Outlook and Revenue Forecast

On the guidance front, NeuroPace reiterates its 2026 revenue forecast anchored to core RNS revenue growth from existing indications. The guidance anticipates 20% to 22% growth in core RNS revenue, excluding additional contributions from new indications like idiopathic generalized epilepsy (IGE). In practical terms, the company is signaling that the 2026 topline will rise if the existing RNS installs continue to perform, but the contribution from new markets will be an important swing factor. For context, this is a classic setup: if PMA-S-driven expansion of IGE indications comes through, revenue could surprise to the upside; if not, growth rests more squarely on the volume of existing RNS implementations and the associated service ecosystem.

Regulatory Pushes and Pipeline Catalysts

The Q4 highlights include a regulatory push: NeuroPace submitted PMA-S to the FDA seeking an expanded RNS indication to cover IGE. The NAUTILUS trial results—18-month data showing a robust 77% median seizure reduction with favorable safety—support the PMA-S submission as a potentially meaningful catalyst for future adoption. Investors should watch not only the FDA’s response timeline but also how Medicare and private payers incorporate the expanded indication into reimbursement decisions.

Reimbursement and Market Access Momentum

A notable tailwind cited in the press release: favorable reimbursement updates in the 2026 Outpatient Prospective Payment System Final Rule and the Medicare Physician Fee Schedule. The OPPS Final Rule increases reimbursement for RNS System replacements by about 47% starting January 1, 2026, while the PFS increases are in the 43% to 45% range depending on procedure type. If these adjustments hold, the post-implant economics for hospitals and patients could improve meaningfully, supporting adoption and long-run utilization.

AI Tools and Seizure ID: A Bet on Data and Decision-Making

The company is not resting purely on regulatory or reimbursement bets. NeuroPace references Seizure ID, a suite of NeuroPace AI tools designed to enhance data insights and accelerate iEEG analysis. Seizure ID is positioned as a companion to the RNS platform, aiming to empower clinicians with faster, more confident treatment decisions. Seizure ID has begun its FDA review path in parallel with core RNS expansion plans, signaling a strategic pivot toward software-enabled differentiation in a hardware-heavy market.

What It Could Mean for NPCE and Its Peers

The quarter reinforces a familiar tension for NeuroPace: respectable top-line growth and an improving margin profile, but ongoing profitability challenges amid a high‑capex, R&D-heavy roadmap. The 2026 revenue forecast hinges on two levers: continued demand for the RNS System and successful commercialization of the PMA-S‑driven IGE extension. For peers in the neuromodulation and epilepsy devices space, a few implications emerge:

Regulatory agility matters. FDA timing for PMA-S and any supplemental indications will be a meaningful driver of near-term equity value across the sector.
Reimbursement matters more than ever. The magnitude of OPPS and PFS adjustments could materially shift the cost-of-ownership equation for hospitals and payers, potentially lifting utilization thresholds.
AI-enabled decision support has real appeal, but execution risk is nontrivial. Seizure ID’s FDA review could become a proof point for software-led differentiation in a market that remains implementationally intensive.
Cash runway remains a variable. With a negative Adjusted EBITDA in the current period but stable liquidity, the path to sustained profitability will likely depend on both revenue growth and operating leverage as manufacturing and SG&A scale.

The Matt Levine Take: The Patience Premium

If you squint at NPCE’s numbers through a lawyer’s lens and a strategist’s curiosity, the story feels less like a sprint and more like a careful marathon where the finish line is not just higher revenue but a credible path to cash flow. The Q4 traction and the 2026 revenue forecast imply that the company’s investors are betting on a future where PMA-S approvals, favorable reimbursement, and AI-enabled clinical workflows converge to unlock a more efficient adoption cycle for the RNS System.

EPS and earnings surprises are not the headline this quarter, and that’s not an oversight so much as a reminder that sequencing of regulatory approvals, payer coverage, and new product capabilities will drive the stock’s next leg. In the meantime, the market will likely watch for any shift in the earnings-per-share narrative alongside the revenue trajectory. If Seizure ID and PMA-S deliver in tandem, the industry could start to treat NPCE less as a one-trick device company and more as a platform with recurring revenue potential—assuming, of course, the path to profitability doesn’t trip over an unforeseen regulatory hurdle or a slower-than-expected ramp in hospital adoption.

Bottom Line

NeuroPace’s 2025 results land in line with a narrative of growth tempered by the realities of regulatory-driven bets and the economics of adoption in a specialized medical device market. The 2026 revenue forecast centers on sustained RNS growth, with upside if PMA-S yields expansion into IGE and if reimbursement remains favorable. Seizure ID signals a strategic tilt toward AI-enabled clinical workflows, whose impact—positive or negative—will materialize only as data accrues and regulatory decisions confirm or limit the roadmap.

For investors watching NPCE and the sector, the key near-term prompts are: will EPS appear in upcoming reports, will EPS consensus move higher on better visibility, and will the revenue forecast translate into consistent cash generation? The answer likely depends on a tricky mix of regulatory timing, payer dynamics, and how aggressively NeuroPace can scale its AI-enabled platform alongside its core RNS business.